addiction alberta

Levitee Labs Acquires Five Addiction Clinics in Alberta

  • Levitee acquires the majority of the operating assets of ACT Medical Centres Inc.
  • Five acquired addiction clinics have conducted 35,000+ patient visits over last 12 months
  • Clinics will be integrated with Levitee's growing portfolio of healthcare assets

Levitee Labs Inc. (CSE: LVT) (theĀ " Company " orĀ " Levitee "), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, today announces the completion of the acquisition of the majority of the operating assets of ACT Medical Centres Inc. (" ACT Medical ") as of July 28, 2021. These assets include 5 addiction treatment clinics across the province of Alberta that have conducted over 35,000 patient visits during the past 12 months.

ACT Medical is a community-based organization providing in-depth assessment, customized treatment and counselling to patients suffering from opioid use disorder, chronic pain, and mental health conditions. Each clinic employs a highly educated and specialized team of dedicated physicians, nurses and therapists working in unison with patients to ensure treatment goals are achieved. ACT Medical's clinics are located throughout the province of Alberta, including Calgary, Medicine Hat, Red Deer, Grande Prairie and Lethbridge.

In consideration for the acquisition, Levitee paid $350,000 in cash on the closing date.

Pouya Farmand, CEO of Levitee, states: "We are thrilled to have acquired these five addiction clinics, which directly interface with patients that need alternative medicines and therapies the most. Unfortunately, substance abuse and addiction in Canada is far too prevalent, and current service options do very little to improve the health and wellness of these patients. With innovation and our patient-centric approach, we expect to make a meaningful impact and improve services to the Alberta communities where these clinics are located."

"These assets give us a great start in building our platform for addiction treatment services, with over 20,000 individual patient records and a name brand in the Alberta market," added Ken Osborne, Head of M&A at Levitee. "We are currently evaluating additional accretive opportunities to grow our footprint across Canada."

Levitee intends to integrate these clinics with its current assets in mental health and addiction treatment, as well as assets that are acquired by Levitee in the future.

"Over the past 5 years, ACT Medical has become a leader for the provision of evidence-based treatment programs for people suffering from addictions and chronic pain in Alberta", said Carrie Wylie, Executive Director, ACT Medical. "We are delighted to join the Levitee team on its journey to become a leader in the area of mental health and wellness nationally."

Levitee is also pleased to announce the acquisition of a 5,400 square foot building in Grande Prairie, Alberta. In the future, Levitee intends to use the building to host business operations that are complementary to the Company's mental health and addiction services which are also currently operating in the building.

About ACT Medical Centres Inc.

ACT Medical provides a bridge to recovery. In the continuum of care, it plays a significant role in preparing individuals for recovery. ACT Medical is a community-based organization focused on treating people with opioid use disorder, chronic pain, and mental health issues. ACT Medical has established Care Teams at each of its locations to serve patients. The Care Teams are comprised of a medical director, physicians, nurses, and medical office assistants (MOA's). They provide specialized treatment services as well as provide patients access to recovery programs/beds; access to AISH programs; access to case workers; access to other social supports such as housing support, food services, and dental care, and more. Recovery is the focus of ACT Medical's policies and practices.

About Levitee Labs

Levitee Labs is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee Labs aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies.

Further information about the Company is available on its website at www.leviteelabs.com .

Forward-Looking Statements

This news release contains certainā€Æstatements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statementsā€Ærespecting the Company's planned acquisitions, the closing of same and the expected benefits of same,ā€ÆLevitee'sā€Æbusiness plans and proposed products. Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of Levitee to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information.ā€ÆThese risks and uncertainties include, but are not limited to, those identified and reported in the Company's public filings under the Company's SEDAR profile at www.sedar.com . Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that any such statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whetherā€Æas a result ofā€Ænew information, future events, changes in assumptions, changes in factors affecting such forward-looking statements or otherwise.ā€ÆAny and allā€Æforward-looking information contained in this press release is expressly qualified by this cautionary statement.

The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

For further information about Levitee, please contact:

Levitee Media Contact

media@leviteelabs.com

Levitee Investor and Corporate Communications

ir@leviteelabs.com


News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)

Seelos Therapeutics Announces 1-for-16 Reverse Stock Split

Seelos Therapeutics, Inc. (Nasdaq: SEEL ) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its Board of Directors approved a 1-for-16 reverse stock split of its outstanding shares of common stock, to be effective as ofĀ 12: 01 a.m. Eastern Time on Friday September 27, 2024.

(PRNewsfoto/Seelos Therapeutics, Inc.)

The Company's common stock, par value $0.001 , will begin trading on a reverse stock split-adjusted basis at the opening of the market onĀ Friday, September 27, 2024. Following the reverse stock split, the Company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "SEEL" with the new CUSIP number, 81577F 406. The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement ofĀ $1.00Ā per share of common stock for continued listing on the Nasdaq Capital Market. The reverse stock split was approved by the Company's Board of Directors pursuant to Section 78.207 of the Nevada Revised Statutes and was effectuated by the filing of a Certificate of Change with office of the Nevada Secretary of State.

At the effective time of the reverse split, every sixteen (16) issued and outstanding shares of the Company's common stock will be combined automatically into one (1) share of the Company's common stock without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split, and any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share. The reverse stock split will reduce the number of authorized shares of the Company's common stock from 50,000,000 shares to 3,125,000 shares and the ownership percentage of each stockholder will remain unchanged other than as a result of the rounding of fractional shares. In addition, the reverse stock split will apply to the Company's common stock issuable upon the exercise of the Company's outstanding warrants and stock options, with proportionate adjustments to be made to the exercise prices thereof and under the Company's equity incentive plans, as applicable.

The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 9.2 million to approximately 581 thousand.

About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), as well as early-stage programs inĀ Huntington'sĀ disease, Alzheimer's disease, and Parkinson's disease.

Forward-Looking Statements:
Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the reverse stock split and the timing thereof, the potential impact of the reverse split on the bid price of the Company's common stock, the potential for the Company to regainĀ compliance with the minimum bid price requirement ofĀ $1.00Ā per share of common stock for continued listing on the Nasdaq Capital Market and the expected number of shares of common stock to be outstanding following the reverse stock split. These statements are based on our current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties involved include those associated with general economic and market conditions, as well as other risk factors and matters set forth in our periodic filings with the SEC, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q . Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Contact Information
AnthonyĀ Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL )
300 Park Avenue, 2 nd Floor
New York , NYĀ 10022
(646) 293-2136
anthony.marciano@seelostx.com

Mike Moyer
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401
New York , NYĀ 10019
(617) 308-4306
mmoyer@lifesciadvisors.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-1-for-16-reverse-stock-split-302257773.html

SOURCE Seelos Therapeutics, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
US Food and Drug Administration website on a phone screen.

FDA Finds Kratom Capsules Safe, but Questions About Concentrated Forms Remain

An initial US Food and Drug Administration (FDA) study on kratom, a plant-based substance long consumed in Southeast Asia, has found that the compound appears safe when used in capsule form, even at high doses.

However, a Tuesday (September 17) Bloomberg article notes that the FDA's research did not include kratom-infused drinks or concentrates, which are more common in the US and may carry different risks.

Kratom, a botanical product derived from the leaves of Mitragyna speciosa, has been used in Southeast Asia for centuries, with users traditionally chewing the leaves for its mind-altering effects.

Keep reading...Show less

Compass Pathways to participate in three investor conferences in September

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following September investor conferences:

  • Morgan Stanley 22nd Annual Global Healthcare Conference: fireside chat at 7:45 am ET on September 4, 2024, and host investor meetings
  • H. C. Wainwright 26th Annual Global Investment Conference: fireside chat at 9:30 am ET on September 10, 2024, and host investor meetings
  • Cantor Global Healthcare Conference: fireside chat at 2:30 pm ET on September 17, 2024, and host investor meetings

A live audio webcast of these events will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Canaccord Genuity 44th Annual Growth Conference: presentation at 4:30pm ET on August 13, 2024 and host investor meetings.

A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of this webcast will be accessible for 30 days following such event. For more information, please visit investor section of compasspathways.com.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Psychedelic mushrooms.

Psychedelics Market Update: H1 2024 in Review

The global psychedelics market will likely experience continued growth and interest in the coming years.

According to findings from FactMR, the sector's value is projected to surpass US$603.1 million in 2024, with further growth expected at a CAGR of 7 percent. By 2034, the psychedelics industry is projected to be worth US$1.18 billion.

The field of psychedelics-based therapies has shown significant growth in the past few years as medical companies focus on developing alternative treatments for various mental health conditions, including depression, post-traumatic stress disorder (PTSD), major depressive disorder (MDD), generalized anxiety disorder (GAD), addiction and other ailments.

Keep reading...Show less
Melodiol Global Health

Quarterly Activities Report: Melodiol Delivers $9.3m in Revenue During H1 FY24 ā€“ a 33% Increase the PCP

Melodiol Global Health Limited (ASX:ME1) (ā€˜Melodiolā€™ or ā€˜the Companyā€™) is pleased to provide the following update on progress for the three month period ended 30 June 2024 (the ā€˜quarterā€™), as well as its Appendix 4C. All financial results are in Australian dollars and unaudited (unless otherwise stated).

Keep reading...Show less

Latest Press Releases

Related News

Ɨ